Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31117228 | 1.00 | HTT (0.77) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL11128807 | 0.88 | HTT (0.80) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31117178 | 0.88 | HTT (0.80) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL10340638 | 0.87 | HTT (1.00) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31117093 | 0.87 | HTT (1.00) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL10340640 | 0.87 | HTT (0.78) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL16479382 | 0.86 | HTT (0.73) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1353689 | 0.86 | HTT (0.77) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15779107 | 0.86 | HTT (0.57) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL18987325 | 0.86 | HTT (0.77) | HTTALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619953-A | Dihydropyrazolopyrimidino-pyrido-indol-4-one derivative and application thereof | 新疆工程学院 | 2024-09-10 | — | — | CN | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-108484614-B | Pyrazolo [3,4-d ] pyrimidine-4 (5H) -ketone derivative and preparation method and application thereof | 南开大学 | 2020-01-14 | — | — | CN | disclosed |
| EP-2928474-B1 | DIAZOLE LACTAMS | CHEMOCENTRYX INC (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-2895477-B1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-9487501-B2 | Pyrazole carboxamide compounds and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-11-08 | — | — | US | disclosed |
| WO-2014089495-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014041007-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009055033-A1 | PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055033-A1 | PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | HTT 4748/4885ALDH1A1 923/4885HPGD 1851/4885 |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | IL1B, IL1R1, IL1A | HTT 4738/4885ALDH1A1 703/4885HPGD 383/4885 |
| US-10744118-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | HTT 4748/4885ALDH1A1 923/4885HPGD 1851/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | HTT 4748/4885ALDH1A1 923/4885HPGD 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.